Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab (Q48088703)

8 February 2018

review article

1 reference

title

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab (English)

1 reference

8 February 2018

postmenopausal osteoporosis

main subject

osteoporosis

0 references

1 reference

Ian R Reid

0 references

25 May 2017

1 reference

8 February 2018

published in

BioDrugs

1 reference

8 February 2018

volume

1 reference

8 February 2018

issue

1 reference

8 February 2018

page(s)

289-297

1 reference

8 February 2018

Vitamin D3 and calcium to prevent hip fractures in elderly women

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Calcium intake and risk of fracture: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Pharmacovigilance study of alendronate in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Characterization of and risk factors for the acute-phase response after zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Short-term and long-term effects of osteoporosis therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

High bone density due to a mutation in LDL-receptor-related protein 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

The WNT system: background and its role in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Bone mineral density in sclerosteosis; affected individuals and gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Effects of sclerostin antibodies in animal models of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-017-0229-2

10.1007/S40259-017-0229-2

21 January 2018

Identifiers

DOI

1 reference

8 February 2018

1 reference

8 February 2018